Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Carbamates Stories

2014-04-15 12:29:59

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia. Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of approximately $851.8...

2014-04-01 08:28:25

RARITAN, N.J., April 1, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA(®) in the U.S., with cobicistat, an investigational pharmacokinetic enhancer or boosting agent, developed...

2014-03-28 08:27:31

SentiKin(TM), Kindred Bio's third lead product candidate, is being developed for the treatment of post-operative pain in dogs. SAN FRANCISCO, March 28, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs. SentiKin is a centrally acting non-opioid, non-steroidal...

2014-03-04 12:25:47

SAN FRANCISCO, March 4, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26(th) Annual Growth Stock Conference in Dana Point, CA: Presentation date: March 10, 2014 Presenting time: 1:30 PM PDT Presentation location: Ritz-Carlton, Salon 6 The presentation will be webcast live over the Internet and can be accessed...

2014-02-27 23:35:28

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) February 27, 2014 The prescription drug safety center DrugNews.net is announcing new information on the site for patients taking the blood thinner Pradaxa. A new report shows the maker of the drug, Boehringer Ingelheim, may have kept safety data from the FDA after it was approved in 2010*. DrugNews is a free...

2014-02-11 08:30:37

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer...

2014-02-08 23:03:11

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) February 08, 2014 The prescription drug safety center DrugNews.net is announcing new information on the site for patients taking the blood thinner Pradaxa. Amid lawsuits alleging the drug caused internal bleeding injury or death, a judge has scheduled the first Bellwether trial to start this year*. DrugNews was...

2013-10-22 08:31:39

New Trial Triggers Milestone Payment to Array BOULDER, Colo., Oct. 22, 2013 /PRNewswire/ -- AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Array BioPharma (NASDAQ:...

2013-10-15 04:21:04

BEERSE, Belgium, October 15, 2013 /PRNewswire/ -- Janssen-Cilag International NV (Janssen), today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. (Gilead) for use in...

2013-09-16 08:30:18

Nearly Half of Current Non-Prescribers Anticipate Prescribing Xofigo in the Next Four to Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Sept. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at one month post-launch of Algeta/Bayer HealthCare's Xofigo in the United States, approximately one quarter of surveyed U.S. medical oncologists...